TAZVERIK
PeakSMtazemetostat
NDAORALTABLETPriority Review
Approved
Jan 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Clinical Trials (5)
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
Started Jun 2026
63 enrolled
Follicular Lymphoma
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Started Sep 2025
24 enrolled
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
Started Sep 2025
0Follicular LymphomaRefractory Follicular Lymphoma
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Started Dec 2024
24 enrolled
LymphomaPeripheral T Cell LymphomaAngioimmunoblastic T-cell Lymphoma+2 more
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Started Nov 2023
50 enrolled
Follicular Lymphoma
Loss of Exclusivity
LOE Date
May 3, 2038
148 months away
Patent Expiry
May 3, 2038
Exclusivity Expiry
Jun 18, 2027